Naltrexone Has Variable and Schedule-Dependent Effects on Oral Squamous Cell Carcinoma Cells

Area of Science:

• Oncology
• Pharmacology
• Cancer Cell Biology

Background:

• Oral squamous cell carcinoma (OSCC) survival rates differ significantly between localized (70%) and metastatic (<40%) disease.
• Current OSCC treatments have suboptimal efficacy, necessitating novel therapeutic strategies.
• Naltrexone (NTX), an opioid antagonist, shows promise at low doses for other cancers.

Purpose of the Study:

• To evaluate the effectiveness of intermittent low-dose naltrexone (NTX) on oral cancer cell survival.
• To assess NTX as a single agent and in combination with cisplatin or docetaxel.
• To investigate varying NTX dosing schedules (intermittent vs. continuous).

Main Methods:

• Two human OSCC cell lines (SCC-25, Detroit 562) were treated with NTX (1 µM, 10 µM) alone or combined with chemotherapy.
• Intermittent NTX dosing regimens (5 h once, 5 h daily, 5 h every other day) and continuous exposure were employed.
• Cell viability was assessed using Sulphorhodamine B (SRB) and Cell Counting Kit-8 (CCK-8) assays; statistical analysis used ANOVA.

Main Results:

• Low-dose NTX as a single agent did not produce significant or consistent changes in OSCC cell survival across regimens.
• Combination therapy with NTX and chemotherapy reduced cell viability more effectively than chemotherapy alone at select doses.
• Intermittent short-term NTX pretreatment schedules showed enhanced efficacy, but overall dose response indicated antagonism between NTX and chemotherapy.

Conclusions:

• The effectiveness of low-dose naltrexone in oral cancer warrants further investigation due to observed antagonism with chemotherapy.
• Specific intermittent pretreatment schedules may offer benefits, but require optimization.
• Findings contrast with previous studies in other cancers, highlighting the need for further research into clinical benefit and reproducibility.